Search research articles
Contact Us
Filters
Showing results (61-70 of 77) with videos related to
Page
of 8
Sort By:
Gynecologic Oncology
|
March 1, 1991
Combination chemotherapy in advanced adenocarcinoma of the fallopian tube
H G Muntz, H M Tarraza, B A Goff, et al.
Gynecologic Oncology
|
December 1, 1995
Uterine papillary serous carcinoma (UPSC): a clinicopathologic study of 30 cases
D T Kato, J A Ferry, A Goodman, et al.
Gynecologic Oncology
|
June 15, 1999
Predictors of recurrence in surgical stage II endometrial adenocarcinoma
C M Feltmate, L R Duska, Y Chang, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
December 14, 2005
A phase II study of fixed dose rate gemcitabine in patients with relapsed müllerian tumors
R T Penson, S M Campos, M V Seiden, et al.
Gynecologic Oncology
|
March 29, 2006
Phase I/II dose finding study of combination cisplatin and gemcitabine in patients with recurrent cervix cancer
U A Matulonis, S Campos, L Duska, et al.
Recent Progress in Hormone Research
|
January 1, 1987
Müllerian inhibiting substance: gene structure and mechanism of action of a fetal regressor
P K Donahoe, R L Cate, D T MacLaughlin, et al.
Gynecologic Oncology
|
May 2, 2001
The clinical utility of liposomal doxorubicin in recurrent ovarian cancer
S M Campos, R T Penson, A R Mays, et al.
Reviews of Infectious Diseases
|
September 1, 1988
Detached ciliary tufts mistaken for peritoneal parasites: a warning
D R Kuritzkes, M Rein, S Horowitz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 2, 1999
A Phase I study of continuous infusion doxorubicin and paclitaxel chemotherapy with granulocyte colony-stimulating factor for relapsed epithelial ovarian cancer
L R Duska, R Penson, J G Supko, et al.
The New England Journal of Medicine
|
February 23, 1992
Müllerian inhibiting substance as a marker for ovarian sex-cord tumor
M L Gustafson, M M Lee, R E Scully, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 77) with videos related to
Sort By:
Page
of 8
Gynecologic Oncology
|
March 1, 1991
Combination chemotherapy in advanced adenocarcinoma of the fallopian tube
H G Muntz, H M Tarraza, B A Goff, et al.
Gynecologic Oncology
|
December 1, 1995
Uterine papillary serous carcinoma (UPSC): a clinicopathologic study of 30 cases
D T Kato, J A Ferry, A Goodman, et al.
Gynecologic Oncology
|
June 15, 1999
Predictors of recurrence in surgical stage II endometrial adenocarcinoma
C M Feltmate, L R Duska, Y Chang, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
December 14, 2005
A phase II study of fixed dose rate gemcitabine in patients with relapsed müllerian tumors
R T Penson, S M Campos, M V Seiden, et al.
Gynecologic Oncology
|
March 29, 2006
Phase I/II dose finding study of combination cisplatin and gemcitabine in patients with recurrent cervix cancer
U A Matulonis, S Campos, L Duska, et al.
Recent Progress in Hormone Research
|
January 1, 1987
Müllerian inhibiting substance: gene structure and mechanism of action of a fetal regressor
P K Donahoe, R L Cate, D T MacLaughlin, et al.
Gynecologic Oncology
|
May 2, 2001
The clinical utility of liposomal doxorubicin in recurrent ovarian cancer
S M Campos, R T Penson, A R Mays, et al.
Reviews of Infectious Diseases
|
September 1, 1988
Detached ciliary tufts mistaken for peritoneal parasites: a warning
D R Kuritzkes, M Rein, S Horowitz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 2, 1999
A Phase I study of continuous infusion doxorubicin and paclitaxel chemotherapy with granulocyte colony-stimulating factor for relapsed epithelial ovarian cancer
L R Duska, R Penson, J G Supko, et al.
The New England Journal of Medicine
|
February 23, 1992
Müllerian inhibiting substance as a marker for ovarian sex-cord tumor
M L Gustafson, M M Lee, R E Scully, et al.
Page
of 8